R3Mab / Roche 
Welcome,         Profile    Billing    Logout  
 0 Diseases   0 Trials   0 Trials   77 News 
  • ||||||||||  patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD), R3Mab / Roche, seribantumab (MM-121) / Elevation Oncology
    Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers (Section 21) -  Mar 5, 2024 - Abstract #AACR2024AACR_5289;    
    Results from in vitro and in vivo studies highlight the promising therapeutic potential of a seribantumab-based ADC for patients with HER3-expressing cancers. Additional results on the optimization and characterization of HER3-ADC1 will be presented.
  • ||||||||||  R3Mab / Roche
    Preclinical, Journal:  The study of the role of purified anti-mouse CD193 (CCR3) antibody in allergic rhinitis mouse animal models. (Pubmed Central) -  Jan 11, 2024   
    Its synergistic mechanism of action presents a promising possibility for developing a more potent and the front-line therapeutic solutions in NSCLC patients who have progressed on standard therapies. In this study, we constructed a mouse model of allergic rhinitis and intraperitoneally injected different doses of CCR3 monoclonal antibody (5, 10, and 20
  • ||||||||||  paclitaxel / Generic mfg.
    Targeting of HER3 potentiates the antitumor activity of paclitaxel against triple negative breast cancer (Hall 2-3) -  Nov 4, 2023 - Abstract #SABCS2023SABCS_689;    
    In this study, we constructed a mouse model of allergic rhinitis and intraperitoneally injected different doses of CCR3 monoclonal antibody (5, 10, and 20 Our data demonstrate that increased HER3 is an effective therapeutic target for TNBC and our anti-HER3 mAb (4A7) may enhance the efficacy of paclitaxel in TNBC.
  • ||||||||||  DM002 / Doma Pharma, Biocytogen
    A first-in-class bispecific antibody-drug conjugate (DM002) targeting HER3 and the juxtamembrane domain of MUC1 (Section 36; Poster Board #7) -  Mar 14, 2023 - Abstract #AACR2023AACR_5706;    
    DM002 candidates showed robust anti-tumor activity in multiple CDX and PDX models of lung, breast, gastric and pancreatic cancer; most notably, DM002 candidates outperformed benchmark ADCs in BP0508 lung PDX models. Together, these data indicate that DM002 will be a promising therapeutic drug for patients with HER3 and MUC1 co-expressing tumors.
  • ||||||||||  BL-B01D1 / Biokin Pharma
    BL-B01D1, a novel EGFR (Section 13; Poster Board #10) -  Mar 14, 2023 - Abstract #AACR2023AACR_4868;    
    The clinical phase I has been progressing and the available data exhibit excellent efficacy but low levels of targeted toxicity in the non-small cell lung cancer (NSCLC) treatment setting. Overall, these data suggest BL-B01D1 has potential to serve as a novel, efficacious therapeutic agent for NSCLC with similar therapeutic impact as DS-8201 has in breast cancer treatment.
  • ||||||||||  R3Mab / Roche, Herceptin (trastuzumab) / Roche, Nerlynx (neratinib) / Puma, Knight Therap, Pierre Fabre
    Her2 interaction domain mutations in breast cancer patients are responsible for receptor switch and therapy failure against Her2 targeted medicines (Poster Area) -  Jun 28, 2022 - Abstract #EACR2022EACR_664;    
    BC cells over-expressing HER2-WT or S305C were found sensitive to Trastuzumab (P>0.001) or Neratinib (P>0.001), whereas cells with G309A, S310Y or P523S mutation were non-responder to those drugs as revealed by short-term, long-term viability, anchorage-independent growth and Immunoblot assessments. Conclusion The structural changes ensued after HER2 interaction domain mutations alters the downstream signalling cascades and impacts the therapy response to HER2 targeted medicines.
  • ||||||||||  R3Mab / Roche
    Preclinical, Journal:  CMab-3: A Monoclonal Antibody for Mouse CC Chemokine Receptor 3 for Flow Cytometry. (Pubmed Central) -  May 3, 2022   
    Kinetic analyses using flow cytometry indicated that Ks of CMab-3 for CHO/mCCR3, P388, and J774-1 cells were 4.3 × 10 M, 2.6 × 10 M, and 2.4 × 10 M, respectively. CMab-3 could be a valuable tool for elucidating mCCR3-related biological response using flow cytometry.
  • ||||||||||  R3Mab / Roche
    Preclinical, Journal:  Establishment of Novel Anti-Mouse CCR3 Monoclonal Antibodies (CMab-6 and CMab-7) by N-terminal Peptide Immunization. (Pubmed Central) -  May 3, 2022   
    Kinetic analyses using flow cytometry indicated that the dissociation constants (Ks) of CMab-6 for CHO/mCCR3, P388, and J774-1 cells were 8.7 × 10 M, 1.4 × 10 M, and 1.7 × 10 M, respectively, whereas the Ks of CMab-7 for these cell lines were 3.7 × 10 M, 5.1 × 10 M, and 3.1 × 10 M, respectively. Results also indicated that CMab-6 and CMab-7 are useful for detecting cells expressing CCR3 through flow cytometry, thereby making them potentially beneficial for treating CCR3-expressing cells.
  • ||||||||||  R3Mab / Roche, Herceptin (trastuzumab) / Roche
    Preclinical, Journal:  Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies. (Pubmed Central) -  Apr 29, 2022   
    Results also indicated that CMab-6 and CMab-7 are useful for detecting cells expressing CCR3 through flow cytometry, thereby making them potentially beneficial for treating CCR3-expressing cells. Some of the anti-HER3 MAbs produced in this study displayed tumor inhibitory function and may be considered promising candidates for future HER3-targeted cancer therapy.
  • ||||||||||  R3Mab / Roche
    Journal:  Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution. (Pubmed Central) -  Apr 19, 2022   
    This ChemR23 mAb accelerated acute inflammation resolution and triggered resolution in ongoing chronic colitis models, with a significant decrease in tissue lesions, fibrosis and inflammation-driven tumors. Our findings suggest that failure of current IBD therapies may be associated with neutrophil infiltration and that ChemR23 is a promising therapeutic target for chronic inflammation.
  • ||||||||||  R3Mab / Roche
    [VIRTUAL] Neurotensin increases tyrosine phosphorylation of HER3 () -  Mar 13, 2021 - Abstract #AACR2021AACR_4820;    
    The results indicate that NTS increased HER3 tyrosine phosphorylation in a ROS-/Src-/MMP-dependent manner. In summary, NTSR1 transactivates HER3 resulting in ERK and Akt phosphorylation increasing the proliferation and survival of NSCLC cells.
  • ||||||||||  R3Mab / Roche
    [VIRTUAL] Triggering the resolution of inflammation with agonistic anti-ChemR23 antibody dampens inflammation-driven carcinogenesis () -  Mar 13, 2021 - Abstract #AACR2021AACR_4185;    
    Finally, using an orthotopic triple-negative breast cancer model (4T1), while we observed a limited impact on primary tumor growth, spontaneous metastasis development in the lung was significantly inhibited by the ChemR23 agonist mAb monotherapy. Our study reveals for the first time the therapeutic potential of triggering the proresolutive pathways using an anti-ChemR23 agonistic mAb to limit chronic inflammation in the tumor microenvironment and inhibit metastasis development.
  • ||||||||||  R3Mab / Roche
    [VIRTUAL] Neurotensin causes tyrosine phosphorylation of HER3 () -  Mar 11, 2021 - Abstract #AACR2021AACR_2194;    
    The results indicate that NTS increased HER3 tyrosine phosphorylation in a ROS-/Src-/MMP-dependent manner. In summary, NTSR1 transactivates HER3 resulting in ERK and Akt phosphorylation increasing the proliferation and survival of NSCLC cells.
  • ||||||||||  R3Mab / Roche
    Preclinical, Journal:  Process intensification in fed-batch production bioreactors using non-perfusion seed cultures. (Pubmed Central) -  Jun 19, 2020   
    The non-perfusion N-1 methodologies reported here are much simpler alternatives in operation for process development, process characterization, and large-scale commercial manufacturing compared to perfusion N-1 seeds that require perfusion equipment, as well as preparation and storage vessels to accommodate large volumes of perfusion media. Although only 3 stable mAbs produced by CHO cell cultures are used in this study, the basic principles of the non-perfusion N-1 seed strategies for shortening seed train and production culture duration or improving titer should be applicable to other protein production by different mammalian cells and other hosts at any scale biologics facilities.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Vizimpro (dacomitinib) / Pfizer
    Journal:  The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. (Pubmed Central) -  Dec 23, 2019   
    This technique might allow for easier transition of mutation-based biomarkers to IHC and improve turnaround time and access for predictive tests in oncology. Our findings indicate that dacomitinib-mediated blockade of the ERBB receptors yields advantages over single-targeted ERBB inhibition and provide a rationale for further investigation of the therapeutic potential of dacomitinib in the treatment of ERBB-driven PDAC.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Addition of anti-VEGF overcomes the anti-PD-L1 refractoriness in a OV2944-HM-1 tumor model (Board 46: Level 2 - Hall D) -  Sep 18, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_274;    
    At least in the anti-PD-L1 insensitive model, this can be mainly explained by the maintained increase of intratumoral CXCL9 leading to the increased infiltration of activated effector CD8+ T cells into tumor tissue. Conflict of interest: The authors are employees of Chugai Pharmaceutical Co., Ltd.